August 8, 2026

GLP-1 medications have reshaped how medicine approaches weight management and blood sugar control. But researchers are now uncovering something unexpected: these medications may also influence how people experience alcohol cravings. Early clinical evidence—particularly involving semaglutide—has found reductions in alcohol craving and, in some cases, decreases in alcohol consumption among study participants. This does not mean […]

You sit down after a long day, and before you know it, you’re halfway through a bag of chips—despite having eaten dinner an hour ago. Sound familiar? For many people, eating isn’t always about hunger. Stress, boredom, sadness, anxiety, and even habitual cues like watching TV can all prompt a trip to the kitchen. Understanding

Arizona summers don’t ease anyone in gently. Temperatures in Phoenix routinely exceed 110°F between June and September, turning something as simple as a walk to the car into a sweaty ordeal. For adults using GLP-1 medications like semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) for medically supervised weight management, that heat adds a layer of

GLP-1 medications like semaglutide and tirzepatide have helped many people achieve meaningful, sustained weight loss by reducing appetite and lowering overall food intake. But as the number on the scale drops, a common concern comes up: am I losing muscle along with fat? It’s a fair question—and an important one. Some reduction in lean mass

If you’ve been eating well, staying active, and still struggling to lose weight, the problem might not be your willpower. For many adults, an underlying metabolic condition called insulin resistance makes weight management significantly harder—and it often goes undetected for years. Understanding how insulin resistance works, what causes it, and how it connects to stubborn

Managing weight with polycystic ovary syndrome (PCOS) can feel like an uphill battle—even when you’re doing everything right. PCOS is a hormonal and metabolic condition that affects roughly 1 in 10 people with ovaries, and it can disrupt everything from blood sugar regulation to appetite control. For many, the connection between PCOS and weight isn’t

Weight loss medications have advanced significantly over the past several years, and a new contender is generating considerable interest among researchers, clinicians, and patients alike. Retatrutide—an investigational injectable developed by Eli Lilly—has drawn attention because it works on hormone pathways that existing medications do not fully address. Early clinical results have been notable. This post

The number on the scale tells only part of the story. Two people can weigh exactly the same and have very different health profiles—because body fat isn’t distributed equally, and where fat is stored can influence health in meaningful ways. Body fat generally falls into two main categories: visceral fat and subcutaneous fat. Understanding the